$3.14Day Range$3.40
Key Statistics
Market Cap
$19.58M
Shares Outstanding
5.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 26, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$3.29
Day High
$3.40
Day Low
$3.14
Volume
4.6K
VWAP
$3.27
Prev Close
$3.32
Transactions
--
Acc. Volume
--
About NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Identifiers
- CIK
- 0001783036
- Ticker Root
- NCEL
About NewcelX Ltd. Ordinary Shares (NCEL) Stock
NewcelX Ltd. Ordinary Shares (NCEL) closed the 2026-09-16 session at $3.39, up 2.11% versus the previous close (+0.07). The stock opened at $3.29 and traded between $3.14 and $3.40 during that session. Session trading volume was 5K shares. The volume-weighted average price (VWAP) is $3.27.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
NewcelX Ltd. Ordinary Shares has a market capitalization of $19.6 million. NCEL is listed on the XNAS exchange. The company employs approximately 4 people. The recorded listing date is 2021-01-26.
On this page you can find market NCEL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.